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Role of Protein Kinase C in Regulation of
Gene Expression and Relevance to Tumor
Promotion
by Mark D. Johnson,* Gerard M. Housey,*t Catherine A.
O'Brian,* Paul T. Kirschmeier,* and 1. Bernard Weinstein**
The tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) has highly pleiotropic effects on cells
in culture and on tissues in vivo, including effects on protein kinase C (PKC) activation and gene expres-
sion. In order to determine the mechanism of activation of gene transcription by TPA, DNA sequences
whose transcription is modulated in cells undergoing a mitogenic response to TPA were isolated by
differential screening ofa cDNA library from TPA-treated cells. TPA-S1 corresponds to an mRNA species
whose abundance is increased within 1 hr ofexposure ofquiescent C3H 10T1/2 mouse embryo fibroblasts.
TPA-R1 corresponds to an mRNAspecieswhoseabundance isdecreased inTPA-treatedcells. Theinduction
of TPA-S1 is blocked by actinomycin D and is specific for phorbol esters with tumor-promoting activity.
The transcription of this sequence is not induced by cycloheximide, nor is there an enhancement of the
TPA response. Several lines of evidence demonstrate that PKC activation plays a critical role in the
regulation of TPA-S1 expression. The nucleotide and predicted amino acid sequence of TPA-S1 exhibits
homology with sequences representing a peptide with erythroid-potentiating activity, a metalloproteinase
inhibitor protein, and a murine protein with 1-interferon-like activity. The role of TPA-S1 in tumor
promotion is suggested by the expression ofthis sequence in mouse skin carcinomas induced by dimethyl-
benzanthracene-TPA treatment, but not in papillomas or in control tissue. The consideration of signal
transduction pathways may be useful in the design of short-term risk assessment assays for agents that
act as tumor promoters.
Introduction
Any scientific approach to the problem ofcarcinogen
risk assessment must consider that carcinogenesis is
usually a multistage process, resulting in profound
alterations in the control of cell proliferation and dif-
ferentiation. The elucidation ofthe basis ofthese alter-
ations is limited by our lack of understanding of the
molecular mechanisms involved in regulation of prolif-
eration and differentiation in normal cells. Recent stud-
ies of the responses of cells to specific growth factors
and modulators ofdifferentiation have identified several
pathways of receptor-mediated signal transduction,
involving specific second messengers (Fig. 1). The bind-
ing of growth factors to their membrane-associated
receptors initiates a cascade of events, leading even-
tually to nuclear events and alterations in gene expres-
sion. It is of interest that several of the characterized
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oncogenes arehomologous to various componentsinsig-
nal transduction pathways and the mitogenic response,
including those related to growth factors (sis), growth
factorreceptors(erb-A, erb-B, neu,fms), andGproteins
that are involved in signal transduction (ras). In addi-
tion, the expression of several oncogenes (myc, fos) is
inducible in response to mitogenic stimulation (1-4).
Therefore, the perturbation of pathways of responses
ofcells to growth factors may be a common mechanism
in the transformation process.
Protein phosphorylation plays a central role in the
signal transduction process (Fig. 1). Membrane recep-
tors for platelet-derived growth factor (PDGF), epi-
dermal growth factor (EGF), insulin, and colony-stim-
ulating factor (CSF) have tyrosine kinase activity (5).
The kinase activity of these receptors is activated by
binding ofthe respective growth factor to the receptor.
In addition, the response ofcells to several mitogens is
mediated, at least in part, by the stimulation of phos-
pholipid turnover, through the activation of the mem-
brane-associated enzyme phospholipase C. This results
in the hydrolysis of phosphatidylinositol 4,5-diphos-
phate to generate diacylglycerol (DAG) and inositol tri-
phosphate (1P3) (6). DAGis an activator ofanimportant
serine and threonine protein kinase, which is Ca +- andJOHNSON ET AL.
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FIGURE 1. A schematic diagram showingvariouspathways ofsignal
transduction that are mediated by protein phosphorylation. The
growth factor receptors include those for EGF, PDGF, insulin,
and colony-stimulating factor, which havetyrosine kinase activity.
The P-adrenergic receptorpathwayinvolvesthecouplingtoadenyl
cyclase (AC) through a Gregulatory protein (Ns). The stimulation
of AC activity results in the synthesis of cAMP, which binds to
the regulatory subunit (R) orprotein kinase A (PKA) and releases
the catalytic activity. The activation of phospholipase C (PL-ase
C), through an associated G protein, results in the generation of
diacylglycerol (DAG), which activates protein kinase C (PKC),
and inositol 1,4,5-triphosphate, which stimulates the release of
calcium from the endoplasmic reticulum. Activation ofthese path-
ways has been associated with the induction ofexpression ofspe-
cific genes, including c-fos and c-myc.
phospholipid-dependent, protein kinase C (PKC). PKC
plays a central role in numerous cellular processes, in-
cluding neurotransmitter release, hormone secretion,
the action of several growth factors, and tumor pro-
motion. PKC also has a wide range of substrates, in-
cluding growth factor receptors, ion channel proteins,
and cytoskeletal proteins (7). Thus, the activation of
PKC can produce a highly pleiotropic response on cells.
Studies in our laboratory, and others, have demon-
strated that PKC represents a complex gene family of
related kinases (isozymes), based on the isolation ofdis-
tinct cDNA clones and the purification ofdistinct forms
of PKC proteins (8). The enzyme has two functional
domains, a carboxy terminal region with consensus se-
quences for ATP binding and for kinase activity, and
an amino terminal regulatory domain, which contains
the putative sites for lipid, Ca2", and phorbol ester
binding. The deduced amino acid sequences from PKC
cDNA clones reveal considerable homology to other
serine and threonine protein kinases, especially the cat-
alytic regions of the cyclic AMP-dependent protein ki-
nase (protein kinase A) and the cyclic GMP-dependent
protein kinase (protein kinase G) (8).
The essential role ofthe PKC pathway in tumor pro-
motion and cellular transformation was suggested by
the observation that PKC is the major receptor for the
potent tumor promoter 12-O-tetradecanoyl phorbol-13-
acetate (TPA) (9), which binds to PKC and mimics the
effect ofDAG in the activation ofthe kinase activity of
PKC (10). The treatment ofcells with TPA and related
tumor promoters induces a highly pleiotropic set ofre-
sponses in vitro, as summarized in Table 1 (11,12). An
important question is whether the activation of PKC
mediates all of these complex effects of TPA on mem-
brane function, mitogenesis, differentiation, and gene
expression. Activators of PKC, such as synthetic dia-
cylglycerols, can mimic many of the effects of TPA in
vitro (13,14). Also, inhibitors ofPKC have been shown
to block specific effects of TPA (15). The observation
that H-ras-transformed fibroblasts have elevated levels
ofdiacylglycerol suggeststhatperturbationsofthePKC
pathway may also be involved in maintenance of the
transformed phenotype in tumor cells (16).
Treatment ofcells with TPA can induce orinhibit the
expression of several mitogen-responsive genes (Table
2) (1,11,17-21). We have recently described the isola-
tion and characterization of a cDNA clone (TPA-S1),
which corresponds to a gene whose expression is mark-
edly increased in murine fibroblasts exposed to TPA.
We have also isolated a cDNA (TPA-R1) that corre-
sponds to a gene whose RNA abundance is markedly
decreased in cells treated with TPA (21). In this paper
we describe these results and provide evidence that the
induction ofTPA-S1 RNAby TPAis mediatedbyPKC.
We also briefly discuss the relevance ofstudies ofPKC
and signal transduction to the development of short-
term assays for tumorpromoters and the science ofrisk
assessment.
Materials and Methods
CellCulture. C3H 1OT1/2mouseembryofibroblasts
(22) were cultured within passage 12 in DMEM medium
(Gibco) with 10% fetal bovine serum (FBS, Flow Lab-
oratories) and 25 U/mL penicillin-25 ,ug/mL strepto-
mycin (Gibco).
Reagents. The chemicalsused inthese studieswere
obtained from the following sources: DMSO (Aldrich
Table 1. Summary of TPA effects.
Tumor promotion
Cell proliferation
Cell morphology
Cell differentiation
Intercellular communication
Membrane transport
Growth factor-receptor binding
Phospholipid metabolism
Protein phosphorylation
Sister chromatid exchange
Gene transcription
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Table 2. Summary of TPA-induced genes.
Protooncogenes Growth modulation Protease modulation Cytoskeleton Other proteins
c-myc Ornithine decarboxylase Plasminogen activator Actin Metallothionein
c-fos Prolactin MEP-Lysosomal protein Vimentin Transglutaminase
c-sis MRP-Proliferin Stromolysin Calcitonin
c-fms PDGF Collagenase
Interleukin-1 Metalloproteinase inhibitor
T-Cell growth factor
BSF-Interferon B2
Interferon-erythroid potentiating
activator
Chemicals); TPA, mezerein and 4a-phorbol didecanoate
(4a-PDD) (LC Services); A23187 (Sigma).
RNA Isolation. Cells in culture plates were rinsed
in cold phosphate-buffered saline (PBS), then lysed in
a 4 M guanidinium thiocyanate (GTC). The RNA was
isolated by centrifugation through a 5.7 M CsCI-0.1 M
EDTA gradient. The poly A' fraction was isolated fol-
lowing two rounds ofselection through an oligo dT cel-
lulose column (21). RNA from mouse tissues was pre-
pared by homogenization offrozen samples and isolated
by a lithium chloride extraction method (23).
RNA Analysis. The RNA samples were elctrop-
horesed through 1% agarose-formaldehyde gels and
blotted onto nylon membranes in 10x SSC. The blots
were hybridized to nick-translated probes (TPA-S1 and
TPA-R1) in 50% formamide, 5 x SSPE, 5 x Denhardt's,
10% dextran sulfate, and 20 ,ug/mL salmon sperm DNA,
then washed with 0.1 x SSC at 68°C and autoradio-
graphed.
Results
A XGT10 cDNA library was synthesized from poly
A' RNA obtained from quiescent C3H 10T1/2 cells 4
hraftertreatment with 100ng/mL TPA. Several clones
were detected by differential hybridization analysis,
two ofwhich were isolated and characterized in detail.
One ofthese corresponded to an RNA species that was
induced by TPA treatment (TPA-S1) and the other to
an RNAspecies inhibited byTPAtreatment (TPA-R1).
Figure2showsaNorthernblotofpolyA' RNAisolated
from control cells and from cells treated with TPA for
4hr, thenhybridized to TPA-S1 and to TPA-R1 probes.
TPA-S1 hybridized to a 0.8 kb transcript that was in-
duced about 20-fold in response to TPA treatment (as
determined by densitometric scan). TPA-R1 hybridized
to a 4 kb transcript whose abundance was markedly
decreased in response to TPA.
The induction of TPA-S1 RNA levels by TPA was
transient, showing an increase after 1 hr oftreatment,
a maximum increase by 9 hr, then a return to basal
levels by 24 hr (21). TPA-S1 was also induced to an
equivalent extentafter4hroftreatmentwithmezerein,
a second-stage tumor promoter (Fig. 3). However, 4a-
PDD, a nonpromoting phorbol ester, had no effect on
TPA-S1 RNA levels, indicating the specificity of TPA-
S1 induction fortumor-promotingphorbols. Also, treat-
ment with the calcium ionophore A23187 showed no
change in TPA-S1 RNA levels, although we have ob-
served an increase in the abundance of ornithine de-
carboxylase RNA (data not presented). Replacing the
culture mediumwith fresh medium containing 10% FBS
resulted in an increased level ofTPA-S1 mRNA, but to
a lesser degree of induction than that observed with
TPA. Addition offresh bovine calforfetal bovine serum
to serum-depleted cultures resulted in a strong induc-
tion of TPA-S1 expression (data not presented). The
role ofPKC in the regulation ofTPA-S1 is based on the
concordance ofagents that activate PKC (TPA, PDGF,
serum, diacylglycerol, and EGF) with their ability to
induce TPA-S1, the ability of PKC inhibitors to block
the induction of TPA-S1 by TPA, and the inhibition of
TPA-S1 inducibility in cells with down-regulated PKC
activity.
TPA treatment ofthe 1OT1/2 cells led to a reduction
of TPA-R1 RNA levels with a time course that was
similar to the TPA induction of TPA-S1 RNA levels.
Mezerein and A23187 also caused a decrease in the lev-
els ofTPA-R1 RNA, while 4ct-PDD had no appreciable
effect (21). Although PDGF, serum, EGF, and diacyl-
glycerol induced an increase in TPA-S1 RNA, the RNA
level of TPA-R1 was not altered by treatment with
these agents (data not presented). The mechanism of
regulation is unclear, but the modulation of TPA-R1
RNA levels may occur by a PKC-independent process.
Northern blot analysis ofRNAs from tissues isolated
after treatment ofmouse skin with DMBA, followed by
repeated TPAdoses [as described in (23)], revealedthat
TPA-S1 mRNA was not detectable in spleen or liver
RNA samples. TPA-S1 was also not detected in papil-
lomas induced by DMBA alone or by DMBA and TPA
treatment. However, TPA-S1 was detected in two skin
carcinomasinducedby DMBAand TPAtreatment (Fig.
4). Interestingly, the mRNA was not observed in tu-
mors induced by DMBA alone. The transcript size was
the same as that observed in mouse fibroblasts (0.8 kb).
Hybridization ofthe TPA-S1 probe to RNA from other
mouse tissues revealed extremely low basal RNA lev-
els, with highest expression in the testes and lung, and
lowest expression in liver, kidney, and brain (data not
presented).
We have determined the complete nucleotide se-
quenceoftheTPA-S1 cDNAclone. Thepredictedamino
acidsequenceindicates apeptide of205aminoacidswith
a molecular weight of 22.6 kd. The amino terminus of
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FIGURE 2. Effect of TPA on the expression of TPA-S1 and TPA-R1 transcripts. Poly A' RNA was isolated from postconfluent C3H
1OT1/2 cells, 4 hr after treatment with either 0.1% DMSO (control) or 100 ng/mL TPA (in 0.1% DMSO). Each lane contains 10 ,ug ofpoly
A+ RNA, electrophoresed through 1.0% agarose-formaldehyde gel, blotted onto nylon membrane, hybridized to 32P-labeled probes ofTPA-
Si or TPA-R1, and then autoradigraphed. Location of ribosomal RNA bands (kb) are indicated.
this sequence contains a hydrophobic region with ho-
mology to signal peptides found in secreted proteins
(21). Comparison of TPA-S1 sequence to the National
Biomedical Research Foundation (NBRF) data base
shows strongest homology (76%-DNA and protein) to a
human cDNA sequence that corresponds to a protein
that has erythroid potentiating activity (EPA) (24) and
also to a human cDNA that corresponds to an inhibitor
ofmetalloproteinases (25). These two human seya-.*:ces
are identical to each other. The alignment of these se-
quenceswith TPA-S1 is showninFigure 5. TPA-S1 also
shows 98% homology to a cDNA sequence that corre-
sponds to a protein that has ,-interferonlike activity
(26). TPA-S1 is identical to another murine sequence
(16C8), isolated independently from a cDNA library
from serum-stimulated cells (27).
Discussion
The responses of cells to mitogens and tumor pro-
moters reveal several common features, which we refer
to as the "mitogenic program" (4). Included in these
responses are effects on the expression ofa specific set
of genes, which demonstrate multiple levels of regula-
tion. The induction ofTPA-S1 by TPA appears to be a
primary affect on gene transcription that does not re-
quire the synthesis ofa trans-acting protein, unlike the
induction ofc-myc in PC12 cells, which requires protein
synthesis for the activation of transcription (28). No
change in the TPA-S1 RNA levels was observed in re-
sponse to inhibition of protein synthesis; however, the
induction of other mitogen-responsive genes, for ex-
ample, c-fos, c-myc, and actin in fibroblasts, apparently
involveslabilerepressorproteinsthatcontroltranscrip-
tion (28). Therefore, the control of gene expression in
the mitogenic program can involve multiple levels of
regulation. Studies onthepatternofexpressionofthese
genes must consider this complexity.
There are at least two possible mechanisms by which
PKC might regulate the transcription ofspecific genes.
One is that the activation ofthe kinase activity leads to
the phosphorylation of proteins that translocate to the
nucleus to activate transcription of a specific set of
genes. An alternative hypothesis is that PKC or afrag-
ment of the enzyme actually enters the nucleus where
it affects transcription. It is ofinterestthat the cystine-
92PROTEIN KINASE C AND GENE EXPRESSION
FIGURE 3. Specificity of TPA-S1 induction by mitogens and tumor
promoters. Postconfluent C3H 1OT1/2 cultures were treated with
0.1% DMSO, 100 ng/mL TPA, 100 ng/mL mezerin, 100 ng/mL 4a-
PDD or 1.0 ,M A23187, in 0.1% DMSO or a medium change with
DMEM-10% fetal bovine serum. Total RNA was isolated after a
4-hr treatment with the various agents, then 10 ,ugofeach sample
was electrophoresed, blotted, hybridized to a 32P-labeled TPA-S1
probe, and autoradiographed.
rich repeat elements in the amino terminal domain of
PKC (29) display homology to sequences in several
DNA-binding proteins, including the estrogen and glu-
cocorticoid receptors (30), and may play a regulatory
function in gene transcription. Although there is no di-
rect evidence for either mechanism, the evidence that
neither TPA (31) norPKC (7) arepresent inappreciable
amounts in the nucleus favors the former mechanism.
Several findings suggest that activation ofPKC may
not be sufficient to explain all ofthe effects ofTPA. The
induction of multinucleated cell formation in HTLV-I-
infected cells by TPA is not affected by PKC inhibitors
(32). The compound bryostatin is a potent activator of
PKC, yet it lacks tumor-promoting activity on mouse
skin and does not mimic the effects of TPA on cell dif-
ferentiation (33). The activation of PKC by diacylgly-
cerols is insufficient to induce the differentiation of
HL60 cells (34). We have observed that the reduction
in TPA-R1 levels by TPA was not mimicked by PDGF,
EGF, serum, or diacylglycerol, nor was the effect of
TPA blocked by PKC inhibitors (unpublished data).
FIGURE 4. Expression ofTPA-S1 in mouse skin tissues and tumors.
HA/ICR mice were treated with dimethylbenz[a]anthracene and
TPA, as described (23). PolyA' RNAwas isolated from liver(L),
spleen (S), papillomas (Pap) and carcinomas (Ca). The RNA from
two animals (nos. 39 and 26) was gel electrophoresed (10 ,ug/sam-
ple), blotted, and hybridized to 32P-labeled TPA-S1 probe and
autoradiographed.
Therefore, it appears that PKC activation may be a
necessary but insufficient step in mediatingmany ofthe
biological effects of TPA. The existence of multiple
forms of PKC that are differentially expressed in dif-
ferent tissues suggests that the regulation and phys-
iological effects of each form may differ. This could ex-
plain some of the above discrepancies. Alternatively,
there may be pathways of responses to TPA that are
not mediated via PKC.
The significance of the homology of TPA-S1 to EPA
(24), to a tissue inhibitor ofmetalloproteinases (TIMP)
(25), and to a ,3-interferon (26) is unclear at present.
Although it has been demonstrated that the EPA and
TIMP activities are TPA-inducible, the role of these
proteins in the biologic effects of TPA and other mito-
gens has not yet been determined. It is ofinterest that
TPA treatment can result in the induction ofproteases,
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* *
TPA-S1 M M A P F A S L A S G I L L L L S L I A S S K A C S C A P
EPA/TIMP - E P W P R T V
TPA-S1 P H P Q T A F C N S D L V I R A K F M G S P E I N E T T L Y
EPA/TIMP V T V Q
TPA-S1 Q R Y K I K M T K M L K G F K A V G N A A D I R Y A Y T P V
EPA/TIMP E Y Q L D F V A
TPA-S1 M E S L C G Y A H K S Q N R S E E F L I T G R L R N G N L H
EPA/TIMP V F R H A K Q D L
* *
TPA-S1 I S A C S F L V P W R T L S P A Q Q R A F S K T Y S A G C G
EPA/TIMP T T VA N S L R G T T V E
* * * *
TPA-S1 V C TV F P CL S I P C K L E SD T H C L W T D Q V L V G S
EPA/TIMP E Q G L Q
* *
TPA-S1 E D -Y Q R S R H F A C L P R NP G L C T W R S L G A R *
EPA/TIMP K GF L E Q R S Q I A*
FIGURE 5. Homology ofTPA-S1 amino acid sequence to human EPA and TIMP. The predicted amino acid sequence ofTPA-S1 is displayed,
based on complete nucleotide sequence analysis (21). The alignment ofthis sequence with the predicted protein sequence for EPA (24) and
TIMP (25) is shown. The first 24 amino acids containthe putative signal sequence ofthe nascentprotein. The mark(I) indicates thepredicted
cleavage site for the signal peptide. Cysteine (C) residues are designated (*). The underlined regions represent the potential glycosylation
sites.
Table 3. Potential assays for tumor promoters based on signal
transduction pathways.
Direct activation of protein kinase C in vitro
Direct activation ofphospholipase C in vitro
Stimulation of DAG production and PI turnover
Induction of translocation ofPKC to membrane
Stimulation ofphosphorylation of PKC substrates
Enhancement of T24-induced transformation in culture
such as plasminogen activator (17) and collagenase (35),
as well as protease inhibitors, such as TIMP (35). These
dualresponses could provide aphysiologicalmechanism
by which cells could perform limited extracellular pro-
teolysis. Therefore, alterations in the balance between
these activities could be an important step in tumor
development, invasion, and metastases. Studies are
now underway to determine the biologic activity of
TPA-S1 protein, using a retroviral expression vector
system.
As the role of signal transduction pathways in the
carcinogenic process is being uncovered, it may be use-
ful to consider how these advances could lead to the
development ofshort-term assays foragents thatmight
act as tumor promoters. Possible assays which could be
used to detect potential tumor promoters and related
compounds are summarized in Table 3. These assays
include the direct or indirect activation ofPKC, which
could be detected byspecific substrate phosphorylation;
the release of endogenous PKC activators; alterations
in PKC-mediated gene transcription; and the enhance-
ment of oncogene-induced transformation (36). At the
presenttime, themajorshort-termtestsforcarcinogens
detect onlygenotoxic agents, which seriously limits the
process of risk assessment. It is hoped that assays of
the type described in Table 3 will broaden the detection
ofagents that can enhance the carcinogenic process and
therefore improve the science ofrisk assessment.
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